<DOC>
	<DOCNO>NCT01327066</DOCNO>
	<brief_summary>The purpose study define electrocardiographic ( ECG ) effect Droxidopa clinical ( 600 mg ) supratherapeutic ( 2000 mg ) dose compare placebo moxifloxacin healthy male female subject .</brief_summary>
	<brief_title>Electrocardiographic ( ECG ) Safety Study Droxidopa Clinical Supratherapeutic Dose</brief_title>
	<detailed_description>This randomize , double blind , single-site , 4 period crossover study healthy male female subject determine droxidopa administer single therapeutic ( 600 mg ) single supratherapeutic ( 2000 mg ) dose delay cardiac repolarization determine measurement QTc interval . Study drug ( droxidopa , placebo , moxifloxacin ) administer double blind , double dummy manner . The central ECG laboratory ( eResearch Technology , Inc , Philadelphia , Pennsylvania ) blind treatment . A total 52 healthy subject ( approximately 26 woman 26 men ) enrol randomly assign treatment sequence . Subjects cross 4 treatment period subject receive single dos follow treatment fast condition separate minimum 3 day washout period ( Day 1 ) : - Droxidopa 600 mg ( therapeutic dose ) , oral capsule - Droxidopa 2000 mg ( supratherapeutic dose ) , oral capsule - Placebo ( match droxidopa ) , oral capsule - Moxifloxacin 400 mg ( positive control ; encapsulate ) , oral Subjects screen study participation Days -21 -2 admit clinic Day -2 Period 1 prestudy assessment . On Day -1 period , subject undergo full day continuous 12 lead Holter monitoring ; 4 ECGs extract H 12+ flash card approximately 1 minute apart 0.5 , 1 , 2 , 3 , 4 , 5 , 6 , 8 , 10 , 12 , 18 , 23 hour . On morning Day 1 period , least 8 hour fast , subject receive single dose study drug accord randomly assign treatment sequence . After dose , subject monitor 23 hour use continuous 12 lead ECG Holter monitor . At ECG core laboratory , 4 ECGs extract approximately 1 minute apart 0.5 , 1 , 2 , 3 , 4 , 5 , 6 , 8 , 10 , 12 , 18 , 23 hour ( Day 2 ) dosing . The ECGs extract Holter record flashcard 10 minute ECG extraction window end onset pharmacokinetic ( PK ) collection nominal time point . Each ECG extraction window precede 10 minute supine rest period . A single 12 lead ECG perform Screening inclusion/exclusion study , baseline safety 12 lead ECG perform Check . In addition , safety 12 lead ECG record review investigator Day 1 period 2 hour dose . Pharmacokinetic blood sample collect Day 1 period dose 0.5 , 1 , 2 , 3 , 4 , 5 , 6 , 8 , 10 , 12 , 18 , 23 hour ( Day 2 ) dosing . Subjects supine least 10 minute time point PK sample . The ECG extraction time match PK sample , obtain actual sampling time avoid change autonomic tone associate psychological aspect blood collection well reduction blood volume subsequent blood collection . Meal time component , activity level , general condition Phase I unit similar possible Day -1 Day 1 treatment period . Subjects discharge Day 2 Period 4 ( ie , 24 hour last dose administer ) . The total study duration approximately 34 day .</detailed_description>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Droxidopa</mesh_term>
	<criteria>1 . Male female subject good general health 18 45 year age , inclusive . 2 . Female subject must nonpregnant , nonlactating , negative serum pregnancy test enrollment study . Female subject childbearing potential ( include perimenopausal woman menstrual bleeding within 1 year ) must use appropriate birth control ( abstinence and/or barrier method and/or oral , injectable , implantable hormonal contraceptive ) entire duration study . Women consider nonchildbearing potential menopausal ( last menstrual period great 12 month Check serum follicle stimulate hormone level great 40 mIU/mL ) surgically sterilize ( documented hysterectomy , tubal ligation , bilateral oophorectomy ) least 6 week Check . 3 . Subject body mass index 18.0 30.0 kg/m2 , inclusive . 4 . Subject provide write informed consent . 5 . Subject willing able comply study requirement . 6 . Subject clinically significant abnormal medical history , clinical laboratory result , vital sign measurement , 12 lead safety ECG result , physical examination finding Screening . 1 . Subject currently participate another clinical study investigational drug ( medical device ) , participate study type within 30 day Check . 2 . Subject history current evidence clinically significant allergic ( except untreated , asymptomatic , seasonal allergy time dose mild allergic reaction drug list exclusion criterion # 16 ) , hematologic , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic disease . Exceptions criterion ( eg , stable mild joint disease , cholecystectomy , childhood asthma ) may make discussion medical monitor . 3 . Subject use prescribed counter medication without approval investigator sponsor within 1 week first dose study drug ( include dietary supplement , herbal remedy , medication know prolong QT/corrected QT [ QTc ] interval ) . 4 . Subject receive anticoagulant ( eg , coumadin , heparin , low molecular weight heparin ) receive anticoagulant within 3 month Check . Subjects receive drug affect platelet function ( eg , aspirin , include lowdose aspirin ) also exclude . 5 . Subject history drug alcohol abuse dependence within 1 year Check . 6 . Subject donate blood blood component within 4 week Check . The investigator instruct subject participate study donate blood blood component 4 week completion study . 7 . Subject sustained supine systolic blood pressure &gt; 140 mm Hg &lt; 90 mm Hg supine diastolic blood pressure &gt; 95 mm Hg &lt; 50 mm Hg Screening Check . Blood pressure may retested supine position . The blood pressure abnormality consider sustain either systolic diastolic pressure value outside state limit 2 assessment , subject may randomize . 8 . Subject rest heart rate ( HR ) &lt; 45 beat per minute &gt; 100 beat per minute vital sign measure Screening Check . 9 . Subject abnormal screening ECG indicate second third degree atrioventricular block , one following : QRS interval &gt; 110 millisecond ( m ) ; QT interval correct HR Fridericia 's formula ( QTcF ) &gt; 450 m ; PR interval &gt; 200 m ; rhythm sinus rhythm interpret investigator clinically significant . 10 . Subject history risk factor torsades de pointes , include unexplained syncope , know long QT syndrome , heart failure , myocardial infarction , angina , clinically significant abnormal laboratory assessment include hypokalemia , hypercalcemia , hypomagnesemia . Subjects also exclude family history long QT syndrome Brugada syndrome . 11 . Subject us use nicotinecontaining product ( eg , cigarette , cigar , chew tobacco , snuff ) within 2 week Check , subject positive cotinine result ( indicate active current smoking ) Screening Check . 12 . Subject consume alcohol xanthinecontaining product ( eg , tea , coffee , chocolate , cola ) within 72 hour Check , subject positive result drug ( ) abuse ethanol Screening Check . 13 . Subject consumes â‰¥ 500 mg per day caffeine ( eg , 5 cup tea coffee ; 8 can five 20 ounce bottle cola ) . 14 . Subject treat investigational agent within 30 day Check ( 5 halflives compound , long ) . 15 . Subject , reason , deem investigator inappropriate study , include subject unable communicate cooperate investigator . 16 . Subject known allergy droxidopa , moxifloxacin , excipient study drug ( ) , encapsulation formulation ( subject exclude mild allergic reaction drug list criterion ) . 17 . Subject receive treatment droxidopa within 30 day Check .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>QTc</keyword>
	<keyword>ECG Effects</keyword>
</DOC>